<DOC>
	<DOCNO>NCT00863291</DOCNO>
	<brief_summary>The acutely suicidal patient present complex dangerous clinical dilemma . Many suicidal patient receive antidepressant medication , onset action medication least three week , despite establish antidepressant effect , show clear anti-suicidal benefit . Psychoanalysts hypothesize depression ( often lead suicidality ) share important characteristic psychological sequellae object loss separation distress . Endogenous opioids ( endorphines ) implicate mediate social bonding separation distress mammal . Anecdotal evidence several clinical study find mixed opioid agonist-antagonist buprenorphine effective antidepressant rapid onset action . It therefore hypothesize buprenorphine may novel quick-acting treatment acute suicidality , especially context depression . The propose double-blind study examine effect buprenorphine acutely suicidal inpatient . Depression , suicidality , overall functioning assess , two-week buprenorphine/placebo trial . A small subgroup patient also treat short-term psychoanalytic psychotherapy throughout study period . It hypothesize subject receive active drug show rapid improvement objective subjective measure suicidality depression .</brief_summary>
	<brief_title>A Double-Blind Study Buprenorphine Treatment Acute Suicidality</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>depression substance alcohol abuse psychosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Depression</keyword>
	<keyword>suicidality</keyword>
	<keyword>buprenorphine</keyword>
</DOC>